Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.73 |
| ▸ | LMNA | P02545 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | NOS3 | P29474 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 8/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 8/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 8/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30917224 | 1.00 | MAPT (0.73) | MAPTLMNASMN1; SMN2PAX8NOS3 | |
| SCHEMBL838415 | 0.92 | MAPT (0.77) | MAPTLMNASMN1; SMN2PAX8NOS3 | |
| SCHEMBL13993033 | 0.85 | LMNA (0.60) | MAPTLMNASMN1; SMN2PAX8NOS3 | |
| SCHEMBL15840668 | 0.73 | MAPT (1.00) | MAPTLMNASMN1; SMN2PAX8CYP2D6 | |
| SCHEMBL6470146 | 0.73 | MAPT (0.61) | MAPTLMNASMN1; SMN2KMT2AHTT | |
| SCHEMBL16440038 | 0.70 | TDP2 (0.62) | MAPTLMNASMN1; SMN2KMT2AXBP1 | |
| SCHEMBL6468016 | 0.70 | NPSR1 (0.59) | MAPTLMNASMN1; SMN2KMT2AHTT | |
| SCHEMBL4650010 | 0.68 | CYP2E1 (1.00) | LMNASMN1; SMN2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2246151 | 0.68 | RAB9A (1.00) | MAPTLMNASMN1; SMN2NOS3NOS1 | |
| SCHEMBL15840766 | 0.67 | MAPT (1.00) | MAPTLMNASMN1; SMN2PAX8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108406-A1 | METHOD OF REGULATING CFTR EXPRESSION AND PROCESSING | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-04-21 | — | — | US | claimed |
| US-11988661-B2 | Rapid quantitative test to diagnose polycystic kidney disease | UMC UTRECHT HOLDING, B.V. (NL) | 2024-05-21 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| EP-3045912-B1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING BV (NL) | 2018-09-19 | — | — | EP | disclosed |
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-08-09 | — | — | US | disclosed |
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2018-08-09 | — | — | US | disclosed |
| US-10006904-B2 | Rapid quantitative assay to measure CFTR function in a primary intestinal culture model | UMC UTRECHT HOLDING B.V. (NL) | 2018-06-26 | — | — | US | disclosed |
| US-20150276719-A2 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-10-01 | — | — | US | disclosed |
| US-20150276719-A2 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-10-01 | — | — | US | disclosed |
| US-20150276719-A2 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-10-01 | — | — | US | disclosed |
| US-20150011420-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150011420-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150011420-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-01-08 | — | — | US | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143295-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221347-A1 | CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE | CFTR, CLCN2, ATP4A | MAPT 3636/4885LMNA 2681/4885SMN1; SMN2 951/4885 |
| US-20160108406-A1 | METHOD OF REGULATING CFTR EXPRESSION AND PROCESSING | CFTR, NEDD8, SCNN1B | MAPT 4644/4885LMNA 1047/4885SMN1; SMN2 2335/4885 |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | CFTR, ABCC5, QPCT | MAPT 4358/4885LMNA 2145/4885SMN1; SMN2 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.